New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07333430
Summary
This early-stage study is testing a new type of CAR-T cell therapy called HBI0101 in adults with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for early signs that the therapy might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah MO, Jerusalem, 9574869
RECRUITINGJerusalem, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.